Form 8-K
Material Company Update
2026-04-07
EDIT filed 8-K — material company event
Editas Medicine, Inc. filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer
Latest SEC filings for Editas Medicine, Inc. (EDIT) explained in plain English: insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). Sourced directly from SEC EDGAR.
Editas Medicine, Inc. filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer
Editas Medicine, Inc. filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer
O'Neill Gilmore Neil (Director, CEO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Parison Amy (SVP, Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Burkly Linda (EVP, CHIEF SCIENTIFIC OFFICER) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.
Editas Medicine, Inc. filed its annual report with the SEC. This report includes audited financial statements, business overview, risk factors, and management discussion.
Editas Medicine, Inc. filed an 8-K with the SEC reporting a material event. Filing excerpt: XBRL Viewer
O'Neill Gilmore Neil, listed as Director, CEO at Editas Medicine, Inc., reported an open-market sale of 5,394 EDIT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Parison Amy, listed as SVP, Chief Financial Officer at Editas Medicine, Inc., reported an open-market sale of 474 EDIT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Burkly Linda, listed as EVP, CHIEF SCIENTIFIC OFFICER at Editas Medicine, Inc., reported an open-market sale of 749 EDIT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
O'Neill Gilmore Neil filed a Form 144 with the SEC indicating intent to sell EDIT (Editas Medicine, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.
Burkly Linda, listed as EVP, CHIEF SCIENTIFIC OFFICER at Editas Medicine, Inc., reported an open-market sale of 713 EDIT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
O'Neill Gilmore Neil, listed as Director, CEO at Editas Medicine, Inc., reported an open-market sale of 5,603 EDIT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
Parison Amy, listed as SVP, Chief Financial Officer at Editas Medicine, Inc., reported an open-market sale of 461 EDIT shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.
O'Neill Gilmore Neil filed a Form 144 with the SEC indicating intent to sell EDIT (Editas Medicine, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.